LifeStance Health Group (LFST) Reports Q3: Everything You Need To Know Ahead Of Earnings

LFST Cover Image

Behavioral health company LifeStance Health (NASDAQ: LFST) will be reporting earnings this Thursday morning. Here’s what you need to know.

LifeStance Health Group met analysts’ revenue expectations last quarter, reporting revenues of $345.3 million, up 10.6% year on year. It was a mixed quarter for the company, with full-year EBITDA guidance topping analysts’ expectations but revenue guidance for next quarter slightly missing analysts’ expectations.

Is LifeStance Health Group a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting LifeStance Health Group’s revenue to grow 13.7% year on year to $355.6 million, slowing from the 19% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.04 per share.

LifeStance Health Group Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. LifeStance Health Group has missed Wall Street’s revenue estimates twice over the last two years.

Looking at LifeStance Health Group’s peers in the outpatient & specialty care segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 7.2%, beating analysts’ expectations by 2.7%, and Encompass Health reported revenues up 9.4%, in line with consensus estimates. Select Medical traded down 2.7% following the results while Encompass Health was also down 7.1%.

Read our full analysis of Select Medical’s results here and Encompass Health’s results here.

Investors in the outpatient & specialty care segment have had steady hands going into earnings, with share prices flat over the last month. LifeStance Health Group is down 10.9% during the same time and is heading into earnings with an average analyst price target of $8.33 (compared to the current share price of $5).

P.S. In tech investing, "Gorillas" are the rare companies that dominate their markets—like Microsoft and Apple did decades ago. Today, the next Gorilla is emerging in AI-powered enterprise software. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.32
+0.00 (0.00%)
AAPL  270.04
+0.00 (0.00%)
AMD  250.05
+0.00 (0.00%)
BAC  53.54
+0.00 (0.00%)
GOOG  278.06
+0.00 (0.00%)
META  627.32
+0.00 (0.00%)
MSFT  514.33
+0.00 (0.00%)
NVDA  198.69
+0.00 (0.00%)
ORCL  248.17
+0.00 (0.00%)
TSLA  444.26
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.